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ABSTRACT: 35 
  36 
The synthesis of six novel cyclometallated platinum(IV) iodido complexes is accomplished by 37 
intermolecular oxidative addition of methyl iodide (compounds 2a–2c) or iodine (compounds 3a–3c) 38 
upon cyclometallated platinum(II) compounds [PtX{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (1a–1c: X = 39 
Cl, CH3 or I). The X-ray molecular structures of platinum(II) compound 1c and platinum(IV) 40 
compounds 3b and 3a’ (an isomer of 3a) are reported. The cytotoxic activity against a panel of human 41 
adenocarcinoma cell lines (A-549 lung, MDA-MB-231 and MCF-7 breast, and HCT-116 colon), DNA 42 
interaction, topoisomerase I, IIα, and cathepsin B inhibition, and cell cycle arrest, apoptosis and ROS 43 
generation of the investigated complexes are presented. Remarkable antiproliferative activity was 44 
observed for most of the synthesized cycloplatinated compounds (series 1–3) in all the selected 45 
carcinoma cell lines. The best inhibition was provided for the octahedral platinum(IV) compounds 2a–46 
2c exhibiting a methyl and an iodido axial ligand. Preliminary biological results point to a different 47 
mechanism of action for the investigated compounds. Cyclometallated platinum(II) compounds 1a–1c 48 
modify the DNA migration as cisplatin. In contrast, cyclometallated platinum(IV) compounds 2a–2c and 49 
3a–3c did not modify the DNA tertiary structure neither in the absence nor in the presence of ascorbic 50 
acid, which made them incapable of reducing platinum(IV) compounds 2b and 2c in a buffered aqueous 51 
medium (pH 7.40) according to 1H NMR experiments. Remarkable topoisomerase IIα inhibitory 52 
activity is reported for platinum(IV) complexes 2b and 3a and in addition, for the last one, a moderate 53 
cathepsin B inhibition is reported. Cell cycle arrest (decrease in G0/G1 and G2 phases and arrest in the S 54 
phase), induction of apoptosis and ROS generation are related to the antiproliferative activity of some 55 
representative octahedral cyclometallated platinum(IV) compounds (2band 2c). 56 
  57 
INTRODUCTION 58 
 59 
Following the well-established square-planar platinum(II) anticancer drugs, octahedral platinum(IV) 60 
complexes currently attract a great deal of attention as they display a number of advantages related to 61 
their inertness and to the possibility of tuning their properties through the additional axial ligands.1–4 62 
Although several platinum(IV) complexes have undergone clinical trials, none has been approved to 63 
date, and the rational design of new platinum(IV) potential antitumor agents still remains a challenge. 64 
On the other hand, in the last few years, the antitumor properties of cyclometallated platinum(II) 65 
compounds have been studied by several groups5–12 including ours.13–16 These compounds present 66 
several advantages such as high stability and increased lability of the leaving groups due to the strong 67 
transeffect of C-donor ligands. Surprisingly, very little attention has been devoted to cyclometallated 68 
platinum(IV) compounds16,17 although these species combine the properties imparted by the presence 69 
of a platinum(IV) center and a cyclometallated ligand. 70 
Cyclometallated platinum(IV) compounds can be obtained in a straightforward process consisting of 71 
intramolecular C–X bond activation from an adequate platinum(II) substrate and a potentially tridentate 72 
[C,N,N′] ligand (method A in Scheme 1).16,18–22 Alternatively, these compounds can be 73 
obtained in a two-step process in which the previous synthesis of cyclometallated platinum(II) 74 
compounds is followed by intermolecular oxidative addition (method B in Scheme 1). The second route 75 
presents some advantages since it allows the synthesis of cyclometallated platinum(IV) compounds with 76 
either identical or distinct axial ligands as well as a direct comparison of the properties of the 77 
platinum(IV) compounds with those of the parent cyclometallated platinum(II) compound. Moreover, in 78 
these compounds, the nature of the axial ligands Y, Z and that of the equatorial ligand X (see Scheme 1) 79 
can be easily modified. 80 
Intermolecular oxidative addition has been extensively studied on square-planar platinum(II) 81 
compounds and it is generally observed that the set of equatorial ligands of the resulting platinum(IV) 82 
compounds retain the stereochemistry of the starting platinum(II) compound while the new ligands 83 
occupy the axial positions.23,24 Intermolecular oxidative addition on coordination compounds such as 84 
cisplatin, carboplatin and their analogues is often the method of choice to prepare platinum(IV) prodrugs 85 
with the most widely used oxidizing agents being halogens or hydrogen peroxide.25–31 86 
Oxidative addition reactions on cyclometallated platinum(II) compounds have received less attention 87 
and often involve reagents such as methyl iodide.32–35 In this work, the oxidative addition of both 88 
methyl iodide and iodine to several cyclometallated platinum(II) compounds was studied with the 89 
purpose of developing a systematic method to prepare novel octahedral cyclometallated platinum(IV) 90 
compounds potentially useful as antitumor agents. 91 
.  92 
RESULTS AND DISCUSSION 93 
 94 
Syntheses and characterization 95 
Three [C,N,N′] cyclometallated platinum(II) compounds of the general formula 96 
[PtX{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (1a–1c) were prepared from imine (CH3)2N(CH2)3NCH(4-97 
ClC6H3) and adequate platinum precursors (see Scheme 2). The synthesis of compound 1a (X = Cl) 98 
from cis-[PtCl2(dmso)2] and the molecular structure of 1a have been previously reported.36 Compound 99 
1b (X = CH3) was prepared from [Pt2(CH3)4{μ-S (CH3)2}2] following previously reported procedures 100 
for analogous compounds.19,37 Interest in compounds containing a methyl ligand arises from the fact 101 
that additional C-donor ligands might further increase both the stability of the compound and the lability 102 
of the ligand in trans. In addition, in view of the renewed interest in iodinated platinum(II) complexes as 103 
antitumor agents,38–40 platinum(II) compound 1c containing an iodido ligand was also prepared in this 104 
work. This compound was initially obtained from the reaction of 1a with AgNO3, followed by a 105 
reaction with potassium iodide. However, better yields and purity were achieved using cis-106 
[PtI2(dmso)2]41 as a metallating agent, reaction conditions similar to those previously described for the 107 
synthesis of 1a36 and a reaction time of 48 hours. The structure of compound 1c was determined 108 
crystallographically and is shown in Fig. 1. As expected,19,36,37 the metallacycle adopts a practically 109 
planar arrangement and is nearly coplanar with the coordination plane, the dihedral angle between the 110 
mean planes being 4.02°. Although the chelate six-membered ring deviates from planarity, the mean 111 
plane of the (N,N′) chelate is only tilted 7.17° from the coordination plane. Most bond angles at 112 
platinum are close to the ideal value of 90°, and the smallest angle (80.64°) corresponds to the 113 
metallacycle. A comparison of the bond distances with those of 1a reveals that the presence of an iodido 114 
instead of a chlorido ligand shortens the Pt–Nimine bond in trans while the bond distances in cis (Pt–115 
N(CH3)2 and Pt–C) are elongated. 116 
In addition, the new cyclometallated platinum(II) compounds 1b and 1c were characterized by NMR 117 
spectroscopy. For both compounds, N(CH3)2 appears as a singlet integrating for 6H and coupled to 118 
platinum and the imine proton is also coupled to platinum. The 3J (Pt–H) values (59.6 Hz for 1b and 119 
139.0 Hz for 1c) are consistent with the presence of a methyl or an iodido ligand in trans, respectively. 120 
In addition, the aromatic proton Ha is also coupled to 195Pt (3J (Pt–H) = 65.2 Hz for 1b and 48.6 Hz for 121 
1c) and is down-field shifted for 1c when compared to 1b (8.75 vs. 7.63 ppm). 122 
Oxidative addition reactions with methyl iodide and iodine were carried out on compounds 1a–1c in 123 
order to produce octahedral cyclometallated platinum(IV) compounds containing either two distinct (2a–124 
2c) or two identical (3a–3c) ligands in the axial positions (see Scheme 1). The proposed mechanisms for 125 
both methyl iodide24 and iodine42 oxidative addition reactions point to the formation of octahedral 126 
platinum(IV) compounds in which the new ligands are mutually trans as depicted in Scheme 3. 127 
Nevertheless, further isomerization reactions might bring these ligands to mutually cis positions. 128 
Compound 1b containing an electron-donating methyl ligand is expected to react more readily in these 129 
reactions. In fact, the oxidative addition reactions took place in all cases but it was observed that while 130 
the reaction of 1b with CH3I is completed in one hour, 1a and 1c require longer reaction times. The 131 
obtained compounds 2a–2c were characterized by 1H NMR spectra in which the N(CH3)2 and the 132 
(CH2)3 protons are diastereotopic due to the absence of a symmetry plane. In contrast, compounds 3a–133 
3c obtained in the reactions with iodine display simpler 1H NMR spectra due to the equivalence of the 134 
dimethylamino and the methylene protons. Selected 1H NMR data of platinum(IV) compounds 2a–2c 135 
and 3a–3c are collected in Table 1 along with those obtained for the parent platinum(II) compounds 1a–136 
1c. 137 
The expected reduction of J (Pt–H) values upon oxidation18,19,43 is observed for the imine proton 138 
when platinum(IV) compounds are compared with the corresponding parent platinum(II) precursor (2a 139 
and 3a vs.1a, 2b and 3b vs. 1b, 2c and 3c vs. 1c) and as indicated for platinum(II) compounds, the value 140 
of this coupling constant strongly depends on the nature of the group in trans to the imine. The values of 141 
2J (Pt–H) for the methyl ligand also decrease upon oxidation of the platinum,19 for instance 2J (Pt–H) = 142 
80.8 Hz for 1b decreases to 69.2 Hz upon oxidative addition of iodine (3b). It is interesting to point out 143 
that compounds 2c and 3b are geometric isomers with the methyl ligand, either trans to the iodido ligand 144 
(2c) or to the imine group (3b). The methyl-platinum protons of these isomers are observed at distinct 145 
chemical shift values (1.71 (2c) vs. 2.21 ppm (3b)) while only a small difference in the 2J (Pt–H) values 146 
is observed (65.5 vs. 69.2 Hz, respectively). Similar 2J (Pt–H) values are obtained for 2b which contains 147 
two methyl ligands, the equatorial trans to an imine and the axial trans to an iodido ligand. In addition, 148 
compound 3b was characterized crystallographically (see below).  149 
While compounds 2a, 2c, 3b and 3c are obtained as a single isomer according to the obtained NMR 150 
spectra, a careful inspection of the 1H NMR spectra of the cyclometallated platinum(IV) compounds 2b 151 
and 3a reveals the presence of a minor isomer in an amount of less than 10% of the mixture. The 152 
isomerization of compound 3a could arise from the exchange of the positions of the chlorido and the 153 
iodide ligands leading to 3a′ depicted in Scheme 4. This is consistent with the fact that compound 3c, 154 
containing only iodide ligands, does not show isomerization. In addition, upon crystallization of 3a in 155 
dichloromethane–methanol mixtures, crystals of 3a′ were obtained as deduced from crystallographic 156 
analyses (see below). In contrast, the presence of a minor isomer of 2b should be assigned to the 157 
I/N(CH3)2 exchange leading to compound 2b″, since the three C-donor ligands always adopt a fac-PtC3 158 
arrangement in octahedral platinum(IV) compounds. 17,19,20 This type of mer- to fac-[C,N,N′] 159 
isomerization has been described for analogous cyclometallated platinum(IV) compounds containing 160 
three C-donor ligands.19,20 161 
The structures of 3b and 3a′ were determined crystallographically and are shown in Fig. 2 and 3, 162 
respectively. For 3b, two independent molecules with bond parameters equal within the experimental 163 
error [3σ] are present in the asymmetric unit. As expected from NMR studies, for both 3b and 3a′, the 164 
platinum atom displays an octahedral coordination with a meridional tridentate [C,N,N′] ligand. An 165 
equatorial methyl and two axial iodido ligands (3b) or an axial chloride and two mutually cis iodido 166 
ligands (3a′) complete the coordination around the platinum. The main distortion from the ideal 167 
octahedral coordination is due to the small bite angle of the metallacycles (3b, 79.76(8)° and 3a′, 168 
80.5(3)°). In both cases, the metallacycle is planar and nearly coplanar with both the coordination plane 169 
and the mean plane of the (N,N′) chelate. For 3b, the axial ligands form an I–Pt–I angle of 170.128(6)°, 170 
somewhat smaller than that reported for the platinum(IV) prodrug of cisplatin cis,cis,trans- 171 
[Pt(NH3)2Cl2I2].25 A comparison of the bond distances with those of 1c reveals that the equatorial Pt–172 
Nimine, Pt–N(CH3)2 and Pt–C bond lengths are moderately longer for the platinum(IV) compounds 3b 173 
and 3a′. In addition, the Pt–Nimine bond is longer for 3b (trans to the methyl ligand) than for 3a′ (trans 174 
to the iodido ligand) in agreement with the higher trans influence of C-donor ligands. 175 
 176 
Solution studies: stability and reduction behavior with ascorbic acid 177 
The stability of platinum(IV) compounds 2b and 2c in the aqueous biological media was evaluated by 178 
recording the 1H NMR spectra of the compounds (1 mM) in 50 mM phosphate buffer (in D2O, pD 179 
7.40); 2 drops of deuterated DMSO were added to solubilize the compound in the media. The obtained 180 
spectra, shown in the ESI (Fig. S1 and S2†), were compared with those obtained at different storage 181 
periods. For 2b, from the very beginning until the last recorded spectrum after 10 days, the same product 182 
is observed. This compound displays an imine resonance at 8.59 ppm coupled to 195Pt (3J(H–Pt) = 52 183 
Hz) and two methyl resonances coupled to platinum at 0.65 ppm (2J(H–Pt) = 80 Hz) and 0.92 ppm 184 
(2J(H–Pt) = 64 Hz) assigned to the axial and equatorial methyl ligands, respectively. These results are 185 
consistent with a fast substitution of the axial iodido ligand (trans to the axial methyl ligand) in 186 
compound 2b by water or dimethylsulfoxide in agreement with the high trans influence of the carbon 187 
atom. The newly formed solvated species (Ib) is stable after 10 days without any evidence of 188 
decomposition (Fig. S1 in the ESI†). For 2c, two products showed up from the very beginning and the 189 
relative intensities of the signals changed along the monitored period (Fig. S2 in the ESI†). This result 190 
suggests that in this case substitution of both iodido ligands for the solvent might take place sequentially 191 
leading to species Ic and II as shown in Scheme 5. The substitution is faster for the iodido in trans to the 192 
methyl group than for the iodido in trans to the nitrogen atom and the proportion of solvated species II 193 
increases with time while that of species Ic decreases. The replacement of the N(CH3)2 moiety of the 194 
[C,N,N′] ligand by either D2O or d6- DMSO leading to species III cannot be ruled out since platinum 195 
satellites could not be observed clearly for this signal. 196 
The reaction with ascorbic acid, a biologically relevant reducing agent, was monitored by 1H NMR 197 
spectroscopy using analogous conditions [1 mM of platinum(IV) compound + 2 drops of deuterated 198 
DMSO + 50 mM phosphate buffer and 25 Mm ascorbic acid] and the obtained spectra are given in the 199 
ESI (Fig. S3 and S4†). Again, for compounds 2b and 2c, the aromatic and imine regions were most 200 
informative since in these regions neither the solvents nor the ascorbic acid interfere with the signals of 201 
complexes 2b and 2c. No evidence was found for the reduction of the platinum(IV) complexes 2b and 202 
2c to the corresponding reduced platinum(II) compounds 1b and 1c. For 2b, the initially formed species 203 
is stable after ten days as evidenced by the lack of changes in the aromatic and imine regions (Fig. S3 in 204 
the ESI†). The two methylplatinum resonances at 0.45 ppm (2J(H–Pt) = 56 Hz) and 0.92 ppm (2J(H–Pt) 205 
= 64 Hz) also remain unchanged after ten days. A comparison of these values with those observed for 206 
species Ib indicated that the axial methyl signal is shifted from 0.65 ppm (2J(H–Pt) = 80 Hz) to 0.45 207 
ppm (2J(H–Pt) = 56 Hz) and this suggests that the solvent coordinated in trans to the axial methyl in Ib 208 
could be replaced by ascorbic acid, leading to species IV. For 2c, a new species that remains stable after 209 
72 h is formed upon adding the ascorbic acid (Fig. S4 in the ESI†). Since compound 2c displays two 210 
labile Pt–I bonds, the coordination of ascorbic acid in both positions, either as two monodentate or one 211 
bidentate ligand as shown in species V, is possible. In this case, a comparison of the obtained NMR data 212 
with those of Ic suggests that a change of both the axial and the equatorial ligands should affect more the 213 
chemical shift of the aromatic and imine signals of the final product than when exclusively the axial 214 
ligand is changed as for species IV. 215 
  216 
BIOLOGICAL STUDIES 217 
 218 
Antiproliferative assay 219 
The antiproliferative activity of cyclometallated Pt(II) (1a–1c)and cyclometallated Pt(IV) (2a–2c and 220 
3a–3c) complexes along with cisplatin, as a positive control, was determined by using the MTT assay. 221 
The non-small A-549 lung, HCT-116 colon and MCF-7 and MDA-MB-231 breast adenocarcinoma cell 222 
lines were used in the study. The half-maximal inhibitory concentration (IC50) values of cisplatin and 223 
the investigated compounds evaluated after 72 h of drug exposure are depicted in Table 2 and Fig. 4. 224 
Series 1 [square planar Pt(II) compounds] and series 2 an 3 [octahedral Pt(IV) compounds] exhibited 225 
remarkable cytotoxicity in all the carcinoma cell lines selected, although showing great differences in 226 
their cytotoxic effectiveness. Cyclometallated Pt(IV) series 2, with CH3/I as axial ligands, showed the 227 
lowest IC50 values of the series and special sensitivity for A-549 lung (1.42–2.62 μM) and HCT-116 228 
colon (1.26–5.43 μM) and MDA-MB-231 (2.06–3.45 μM) breast cancer cells. Compound 2c, exhibiting 229 
an iodido group in trans to the imine nitrogen, was approximately up to 3.5-, 5- and 5-fold more potent 230 
than cisplatin itself in A-549 lung, HCT-116 colon and MDA-MB-231 breast cells, respectively. 231 
Interestingly, considering the breast adenocarcinoma cells (MDA-MB-231 and MCF-7), series 2 showed 232 
stronger selectivity for the triple negative (ER, PR and HER2 negative) MDA-MB-231 (2.34–3.45 μM) 233 
than for the ER and PR positive MCF7 (6.90–37.78 μM) cancer cells. 234 
 235 
DNA interaction in the presence or absence of ascorbic acid 236 
The interaction of cyclometallated Pt(II) (1a–1c) and cyclometallated Pt(IV) (2a–2c and 3a–3c) 237 
complexes with DNA was assessed by their ability to modify the electrophoretic mobility of the 238 
supercoiled closed circular (sc) and the open circular (oc) forms of pBluescript SK+ plasmid DNA. The 239 
sc form usually moves faster due to its compact structure. 240 
Fig. 5 shows the electrophoretic mobility of pBluescript SK+ plasmid DNA incubated with 241 
cyclometallated series 1, 2 and 3 at increasing concentrations. For comparison, the incubation of DNA 242 
with cisplatin and ethidium bromide (EB) was also performed. 243 
As was expected, based on the previous results, square planar platinacycles 1a–1c alter the mobility of 244 
plasmid DNA (Fig. 5), especially compound 1c. A decrease in mobility was observed at quite high 245 
concentrations tested in the experiment (up to 50 μM for compound 1c and 100 μM for compounds 1a 246 
and 1b). For comparison, the reference cisplatin modifies the DNA electrophoretic migration at a 247 
considerably much lower concentration (2.5 μM). On the basis of this gel mobility shift assay, it is 248 
hypothesized that platinacycles 1a–1c alter the DNA tertiary structure by the same mechanism as the 249 
standard reference, cisplatin, but at higher concentrations. In contrast with these findings, octahedral 250 
Pt(IV) compounds 2a–2c and 3a–3c (Fig. 5) did not modify the plasmid DNA electrophoretic mobility, 251 
pointing to a different mechanism of action or an alternative biomolecular target. It is worth mentioning 252 
that Pt(II) compounds, triggering the greatest effect in the DNA tertiary structure, were not the more 253 
cytotoxic agents of the studied series. 254 
In order to investigate the effect of ascorbic acid on the in vitro activity of the octahedral platinum(IV) 255 
compounds 2a–2c and 3a–3c, further experiments were conducted. Supercoiled pBluescript SK+ 256 
plasmid DNA was co-incubated with series 2 and 3 (0–200 μM) in the absence and presence of ascorbic 257 
acid (500 μM) at 37 °C for 24 h (Fig. 6). No alteration on the DNA electrophoretic mobility was 258 
observed for the Pt(IV) compounds investigated at any of the concentrations tested. Hence it is assumed 259 
that no reduction took place to yield the corresponding platinum(II) cyclometallated compounds 1a–1c, 260 
which were able to modify the DNA migration in the previous electrophoretograms. 261 
These results were in accordance with the above 1H NMR experiments performed in the presence of 262 
ascorbic acid (aqueous solution at pH = 7.40). The reluctance of the Pt(IV) cyclometallated compounds 263 
under study (2a–2c and 3a–3c) to be reduced is also in agreement with the previously published results 264 
on Pt(IV) cyclometallated compounds.17 265 
 266 
Topoisomerase inhibition 267 
Topoisomerases are essential nuclear enzymes that maintain the topological change of DNA and play a 268 
key role in transcription, replication and chromosome segregation.44 Human DNA topoisomerases (topo 269 
I and topo II) are expressed at different levels in different cancer types. For instance, topo I is 270 
overexpressed in colon cancer cell lines, while topo II is overexpressed in breast and ovarian cancer cell 271 
lines.45 Camptothecin and etoposide, topo I and topo II inhibitor, respectively, are clinically approved 272 
anticancer drugs. Human topoisomerases operate in two different ways. One causes single-strand breaks 273 
(SSBs, called type I), and the other induces double-strand breaks (DSBs, type II), during cell 274 
proliferation processes. Between these two types of topoisomerases, topoisomerase II is essential to 275 
relax supercoiled DNA through a catalytic cycle of DSBs.45 There are two isoforms of topoisomerase 276 
II, α and β forms. Despite their similarities, the two enzymes have distinct patterns of expression and 277 
physiological functions in vertebrate cells. The expression level of topoisomerase IIα is up-regulated 278 
dramatically during cell proliferation. 46 It is found at replication forks and remains tightly associated 279 
with chromosomes during mitosis.47 In contrast, the expression of the β isoform is independent of the 280 
proliferative status of cells and the enzyme dissociates from chromosomes during mitosis.48 Therefore, 281 
topoisomerase IIα has been considered as a more attractive target than topoisomerase IIβ for the 282 
development of chemotherapeutic agents.47 283 
To evaluate the ability of the platinum(IV) complexes 2a–2c and 3a–3c to inhibit topoisomerase I or to 284 
intercalate into DNA, a topoisomerase-based gel assay was performed.49 Supercoiled pBluescript 285 
plasmid DNA was incubated in the presence of topoisomerase I at increasing concentrations of 286 
compounds 2 and 3. Ethidium bromide (EB), used as an intercalator control, prevents the shift of 287 
supercoiled DNA into a relaxed state. The results showed that none of the investigated compounds 288 
prevent unwinding of DNA by the action of topoisomerase I, indicating that the compounds are neither 289 
intercalators nor the topoisomerase I inhibitor (not shown). 290 
To evaluate the ability of the platinum(IV) complexes 2a–2c and 3a–3c to inhibit topoisomerase Iiα, a 291 
similar topoisomerase-based gel assay was performed.50 Supercoiled pBluescript plasmid DNA was 292 
incubated in the presence of topoisomerase IIα at increasing concentrations of compounds series 2 and 293 
3. Etoposide was used as a control of the topo IIα inhibitor. Fig. 7 summarizes the topo IIα inhibitory 294 
activity of the assayed compounds. Platinum(IV) complex 3c showed strong topo IIα inhibitory activity 295 
at 100 μM and platinum(IV) complexes 2b and 3a showed considerable topo IIα inhibitory activity at 20 296 
μM. These results are very remarkable, taking into account that, under the conditions of the experiment, 297 
platinacycles 2b, 3a and 3c, in particular 2b and 3a, are by far more potent than the anticancer marketed 298 
drug etoposide. Further experiments are ongoing to study the poison or catalytic character of the 299 
synthesized topo IIα inhibitors.  300 
Cathepsin B inhibition Cathepsin B is a metalloprotease that has been proposed to participate in 301 
metastasis, angiogenesis, and tumor progression in solid tumors. Recently, an excellent correlation 302 
between cathepsin B inhibition and cytotoxicity for some metallacycles has been reported.51 It should 303 
be noted that platinum(IV) compound 3a inhibits cathepsin B (IC50 = 55 ± 4 μM). In contrast, while 304 
compounds 3b and 3c present a very similar chemical structure, platinum(II) compounds 1a–1c and 305 
platinum(IV) compounds 2a–2c did not show any significant cathepsin B inhibitory activity. 306 
 307 
Effect of compounds 2b and 2c on cell cycle distribution 308 
Cell cycle is the organized and monitored process between two mitotic divisions which assure the proper 309 
cell proliferation.52 Cell cycle distribution basically consists of three main phases: quiescent and gap1 310 
(G0 and G1), synthesis (S), and gap2 and mitosis (G2 and M) phases. It is a very tightly regulated set of 311 
events that involves various checkpoints and several proteins which are proposed as antitumor targets, 312 
and any disruption in this machinery causes oncogenesis.52–54 The effect of compounds 2b and 2c (as 313 
representative examples of platinum(IV) compounds) on the cell cycle distribution was studied over the 314 
A-549 lung cancer cell line. A-549 cells were incubated with these compounds at their half maximal 315 
inhibitory concentrations (IC50) for 72 h and then analyzed by Fluorescence Activated Cell Sorting 316 
(FACS) using propidium iodide (PI) staining to quantify the DNA content of each cell population. As 317 
shown in Fig. 8, it is observed that both compounds have a similar decrease in the G0/G1 and G2 phases 318 
while they lead to a significant arrest in the S phase of the cell cycle distribution (over 20%) where the 319 
cells supposedly stop DNA replication. 320 
 321 
Effect of compounds 2b and 2c on apoptosis induction 322 
Organisms have evolved in a way that unhealthy or damaged cells are eliminated from the body in a 323 
programmed cell death mechanism known as apoptosis. Unlike healthy cells, as a cancer hallmark, 324 
cancer cells often avoid the apoptotic stimuli which are caused under increased stress conditions.55,56 325 
Therefore, chemotherapeutic-induced apoptosis is of great interest in cancer therapy. On the other hand, 326 
any alteration in the cell cycle may induce apoptosis,57 and therefore, the apoptotic properties of 327 
compounds 2b and 2c (as representative examples of platinum(IV) compounds) in the A-549 cell line 328 
were investigated. A-549 cells were incubated with these compounds at their half maximal inhibitory 329 
concentrations (IC50) for 72 h and then analyzed by flow cytometry using fluorescein- labeled annexin 330 
V (AV-FITC, annexin V-fluorescein isothiocyanate) and propidium iodide (PI) staining. 331 
Apoptosis starts with the loss of plasma membrane symmetry, and phosphatidylserine (PS) is 332 
translocated from the inner membrane to the outer. In this way, the externally exposed PS can bind to 333 
the annexin V-FITC conjugate with a high affinity in the outer environment of the cell. The integrity of 334 
the cell membrane is lost at the late apoptotic/necrotic stages, thus allowing PI to access the nucleus and 335 
intercalate between the DNA bases.58,59 Flow cytometry analysis with annexin V-FITC staining and PI 336 
accumulation was used to distinguish the non-apoptotic cells (annexin V− and PI−), early apoptotic cells 337 
(annexin V+ and PI−) and late apoptotic/necrotic cells (PI+). 338 
As shown in Fig. 9, both compounds have high apoptotic effects on A-549 cells. Treatment with 339 
compound 2b at its half maximal inhibitory concentrations (IC50) for 72 h resulted in 80% decrease in 340 
the healthy cell population while early apoptotic and necrotic populations increased significantly (35% 341 
and 44%, respectively). Similarly, treatment with compound 2c at its half maximal inhibitory 342 
concentrations (IC50) for 72 h resulted in around 20% decrease in healthy cell population and the 343 
population of early apoptotic cells has increased around 20%. Compound 2c did not induce any 344 
significant necrosis. These results indicate that both compounds, 2b and 2c, have highly potent 345 
antiproliferative effects on the A-549 lung cancer cells. The mechanism of action of the compounds is a 346 
combination of cell cycle arrest and particularly apoptosis induction. Compound 2c mostly induces an 347 
increase in the population of early apoptotic cells, while 2b induces an increase both in apoptotic and 348 
necrotic cells, hence indicating the potential of these compounds to be used in cancer chemotherapy. 349 
 350 
Generation of reactive oxygen species (ROS) 351 
Reactive oxygen species (ROS) include molecules with increased reactivity such as superoxide (O2 −), 352 
hydrogen peroxide (H2O2), hydroxyl radical (•OH) and singlet oxygen (1O2) and are produced in all 353 
cells as normal metabolic by-products. The effect of ROS on cells depends on its concentration, and low 354 
ROS concentrations are reported not only to contribute to cell survival and proliferation as it plays a role 355 
in post translational modification of phosphatases and kinases60,61 but also to be required for 356 
homeostatic signaling events, cell differentiation and cell mediated immunity. While moderate ROS 357 
levels lead to the expression of some stress responsive genes involving HIF-1, which in turn triggers the 358 
expression of prosurvival proteins,62 high ROS levels may induce severe damage to several cellular 359 
macromolecules involving proteins, lipids, nuclear and mitochondrial DNA and cause the induction of 360 
cell senescence or crisis.63 High ROS levels may also lead to permeabilization of mitochondria which 361 
causes the release of cytochrome c and in turn, apoptosis.64 It has been reported that ROS may play an 362 
important role in cisplatin-induced cytotoxicity65 since cisplatin is known to produce ROS.66 363 
Nevertheless, the ROS formation of platinum(IV) complexes has not been studied widely so far. 364 
In this study, the amount of ROS generated by compounds 2b and 2c (as representative examples of 365 
platinum(IV) compounds) in the A-549 cell line was investigated. A-549 cells were incubated with these 366 
compounds at their half maximal inhibitory concentrations (IC50) for 72 h and then analyzed by flow 367 
cytometry using the DFCH-DA (2′,7′-dichlorofluorescein diacetate) assay. As shown in Fig. 10, 368 
compound 2b did not cause significant ROS generation while the production of ROS in A-549 cells 369 
incubated with compound 2c increased significantly compared to control cells. These results are in 370 
accordance with the previous studies exhibiting that certain platinum(IV) complexes are able to induce 371 
elevated ROS levels as part of their biological activities in cancer cells.17,67,68 372 
 373 
  374 
CONCLUSIONS 375 
 376 
A systematic method to prepare novel octahedral cyclometallated platinum(IV) compounds containing 377 
one, two or three labile iodido ligands is presented. Six new cyclometallated platinum(IV) compounds 378 
including two geometrical isomers (2c and 3b) were prepared from the intermolecular oxidative addition 379 
of methyl iodide (compounds 2a–2c) or iodine (compounds 3a–3c) to cyclometallated platinum(II) 380 
compounds [PtX {(CH3)2N(CH2)3NCH(4-ClC6H3)}] (1a–1c: X = Cl, CH3 or I). All compounds were 381 
characterized by NMR spectroscopy and elemental analyses. The molecular structures of platinum(II) 382 
compound 1c and platinum(IV) compounds 3b and 3a′ (an isomer of 3a) were solved by X ray analyses. 383 
The cytotoxic activity against a panel of human adenocarcinoma cell lines (A-549 lung, MDA-MB-231 384 
and MC-7 breast, and HCT-116 colon) was determined for these compounds and the cyclometallated 385 
platinum(II) precursors. All compounds exhibited a remarkable cytotoxicity in all the selected cancer 386 
cell lines and cyclometallated compounds 2a–2c containing a methyl and an iodido axial ligand are the 387 
most potent. The electrophoretic mobility of platinum(II) compounds 1a–1c indicates alteration of the 388 
DNA tertiary structure in a similar way to cisplatin, although at higher concentrations. In contrast, 389 
platinum(IV) compounds 2a–2c and 3a–3c were not effective at all for removing the plasmid DNA 390 
supercoils, not even in the presence of ascorbic acid. Consistently, 1H NMR experiments carried out for 391 
2b and 2c did not show evidence of reduction in the presence of ascorbic acid. Topoisomerase-based gel 392 
assays indicated that none of the compounds 2a–2c and 3a–3c were topoisomerase I inhibitors, but 393 
compounds 2b and 3a, and to a lesser extent 3c showed considerable topo IIα inhibitory activity. In 394 
addition, compound 3a inhibits cathepsin B. Compounds 2b and 2c were found to supress A-549 lung 395 
cancer cell growth by a combination of cell cycle arrest and apoptosis induction. Moreover, compound 396 
2c can induce the ROS levels. As a whole, these studies indicate that these new cyclometallated 397 
platinum(IV) compounds containing iodide ligands display a high potential to be used in cancer 398 
chemotherapy. Their biological properties can be tuned by a careful choice of the nature, number and 399 
arrangement of the iodide ligands in the coordination sphere of platinum(IV). 400 
  401 
EXPERIMENTAL SECTION 402 
 403 
Chemistry 404 
General. Microanalyses were performed at the Centres Científics i Tecnològics (Universitat de 405 
Barcelona). Mass spectra were performed at the Unitat d’Espectrometria de Masses (Universitat de 406 
Barcelona) in a LC/MSD-TOF spectrometer using H2O–CH3CN 1 : 1 to introduce the sample. NMR 407 
spectra were performed at the Unitat de RMN d’Alt Camp de la Universitat de Barcelona using a 408 
Mercury-400 (1H, 400 MHz; 13C, 100.6 MHz) or a Bruker 400 Avance III (195Pt, 85.68 MHz) and 409 
referenced to SiMe4 (1H and 13C) or to H2PtCl6 in D2O (195Pt). δ values are given in ppm and J 410 
values in Hz. Abbreviations used: s = singlet; d = doublet; t = triplet; m = multiplet. 411 
Preparation of the complexes. All reagents were obtained from commercial sources and used as 412 
received. Ligand 4-ClC6H4CHN(CH2)3N(CH3)2 36 and compounds [Pt2(CH3)4{μ-S(CH3)2}2],69 413 
cis-[PtI2(dmso)2],41 and [PtCl{(CH3)2N(CH2)3NCH (4-ClC6H3)}]36 (1a) were prepared as reported 414 
elsewhere. Compound 1a was purified by column chromatography using SiO2 as the stationary phase 415 
and dichloromethane–methanol (100 : 1) as the eluent. 416 
[Pt(CH3){(CH3)2N(CH2)3NCH(4-ClC6H3)}] (1b) was obtained from 0.207 g (0.4 mmol) of 417 
[Pt2(CH3)4{μ-S(CH3)2}2] and 0.146 g (0.7 mmol) of imine 4-ClC6H4CHN(CH2)3N(CH3)2, dissolved 418 
in toluene (40 mL). The mixture was refluxed for 1 hour obtaining a red-garnet solution. The solvent 419 
was removed and the solid was treated with diethyl ether (5 mL) and filtered. Yield: 0.227 g (64%). 1H-420 
NMR (400 MHz, CDCl3): δ 8.56 [s, 3J (Pt–H) = 59.6, 1H, Hd] δ 7.63 [d, 3J (Pt–H) = 65.2, 4J(H–H) = 421 
1.6, 1H, Ha] δ 7.18 [d, 3J(H–H) = 8.0, 1H, Hc] δ 6.95 [dd, 3J(H–H) = 8.0, 4J(H–H) = 2.0, 1H, Hb] δ 422 
3.85 [t, 3J(H–H) = 4.6, 2H, He] δ 2.91 [m, 2H, Hg] δ 2.73 [s, 3J (Pt–H) = 23.6, 6H, Hh] δ 2.02 [qi, 423 
3J(H–H) = 5.1, 2H, Hf ] δ 0.99 [s, 2J (Pt–H) = 80.8, 3H, Hi]. 13C-NMR (100.6 MHz, CDCl3): δ 171.6 424 
[2J (Pt–C) = 82.1, Cd] δ 146.4, 144.9, 136.8 [Caromatics] δ 132.8 [Ca] δ 128.5 [3J (Pt–C) = 45.9, Cc] δ 425 
122.1 [Cb] δ 65.1 [Cf ] δ 56.4 [Ce] δ 49.8 [Ch] δ 27.58 [Cg] δ 10.53 [Ci]. 195Pt-NMR (85.68 MHz, 426 
CDCl3): −3735.55 [s]. Anal. calc. for C13H19ClN2Pt (%): C, 35.99; H, 4.41; N, 6.46. Found (%): C, 427 
35.71; H, 4.58; N, 6.19. 428 
[PtI{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (1c) was obtained from 0.426 g (0.70 mmol) of cis-429 
[PtI2(dmso)2], 0.158 g (0.75 mmol) of imine 4-ClC6H4CHN(CH2)3N(CH3)2 and 0.063 g (0.77 mmol) 430 
of sodium acetate dissolved in methanol (30 mL). The mixture was refluxed for 48 hours, then the 431 
solvent was removed and the solid was extracted with dichloromethane (20 mL) to yield a dark red 432 
solution that was evaporated to dryness. The residue was recrystallized at room temperature from 433 
dichloromethane– methanol. Yield: 0.166 g (44%). Alternatively, compound 1c – slightly impure with 434 
traces of 1a according to the 1H NMR spectrum – was obtained from 1a. 76 mg (0.17 mmol) of 1a were 435 
dissolved in 15 mL of dichloromethane and a solution of AgNO3 (34 mg, 0.20 mmol) in 5 mL of 436 
methanol was added. After stirring for one hour, the mixture was filtered and 60 mg (0.36 mmol) of KI 437 
were added. After stirring for 30 minutes, the solvent was removed and the residue was recrystallized in 438 
dichloromethane–methanol. Yield 0.160 g (42%). 1H-NMR (400 MHz, CDCl3): δ 8.75 [d, 3J (Pt–H) =  439 
48.6, 4J(H–H) = 2.0, 1H, Ha] δ 8.42 [s, 3J (Pt–H) = 139.0, 1H, Hd] δ 7.18 [d, 3J(H–H) = 8.0, 1H, Hc] δ 440 
6.95 [dd, 3J(H–H) = 8.1, 4J(H–H) = 2.0, 1H, Hb] δ 3.84 [td, 3J (Pt–H) = 33.9, 3J(H–H) = 4.6, 4J(H–H) 441 
= 1.6, 2H, He] δ 3.01 [s, 3J (Pt–H) = 16.7, 6H, Hh] δ 2.82 [m, 2H, Hg] δ 2.06 [m, 2H, Hf ]. HRMS-ESI-442 
(+) {H2O :CH3CN (1 : 1)}, m/z: 459.0897 (calc. for C14H19N3ClPt 459.0909) [M − NH4 + CH3CN]+. 443 
Anal. calc. for C12H16ClIN2Pt (%): C, 26.41; H, 2.96; N, 5.13. Found (%): C, 27.60; H, 3.09; N, 5.25.  444 
[Pt(CH3)ClI{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (2a) was obtained from 0.050 g (0.11 mmol) of the 445 
cyclometallated [PtCl{(CH3)2N(CH2)3NCH(4-ClC6H3)}] 1a dissolved in acetone. 1 mL of CH3I was 446 
added and the mixture was stirred for 24 hours. After this time, the solvent was removed, the residue 447 
was washed with diethyl ether (10 mL) and the yellow solid was filtered under vacuum. Yield: 0.034 g 448 
(52%). 1H-NMR (400 MHz, acetone-d6): δ 8.77 [t, 3J (Pt–H) = 116.4, 4J(H–H) = 1.8, 1H, Hd] δ 7.94 449 
[d, 3J (Pt–H) = 32.4, 4J(H–H) = 2.0, 1H, Ha] δ 7.66 [d, 4J (Pt–H) = 4.8, 3J(H–H) = 8.4, 1H, Hc] δ 7.22 450 
[dd, 3J(H–H) = 8.0, 4J(H–H) = 2.0, 1H, Hb] δ 4.30 [m, 2H, He] δ 3.43 [s, 3J (Pt–H) = 11.6, 3H, Hh] δ 451 
2.93 [m, 2H, Hg] δ 2.67 [s, 3J (Pt–H) = 15.2, 3H, Hh′] δ 2.21 [m, 2H, Hf ] δ 1.54 [s, 3J (Pt–H) = 64.8, 452 
3H, Hj]. Anal. calc. for C13H19Cl2IN2Pt·H2O (%): C, 25.42; H, 3.44; N, 4.56. Found (%): C, 24.93; H, 453 
3.02; N, 4.27. 454 
[Pt(CH3)2I{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (2b) was prepared from 0.080 g (0.2 mmol) of 455 
[PtCH3{(CH3)2N(CH2)3NCH (4-ClC6H3)}] 1b using the same procedure and a reaction time of 1 456 
hour. Yield: 0.071 g (67%). 1H-NMR (400 MHz, CDCl3): δ 8.39 [s, 3J (Pt–H) = 47.6, 1H, Hd] δ 7.39 457 
[d, 3J (Pt–H) = 47.0, 3J(H–H) = 8.0, 1H, Ha] δ 7.32 [d, 4J (Pt–H) = 7.6, 3J(H–H) = 8.0, 1H, Hc] δ 7.03 458 
[dd, 3J(H–H) = 8.0, 4J(H–H) = 1.9, 1H, Hb] δ 4.25 [tt, 3J(H–H) = 13.2, 4J(H–H) = 2.6, 1H, He] δ 3.98 459 
[dt, 2J(H–H) = 15.2, 3J(H–H) = 4.2, 1H, He′] δ 3.60 [m, 1H, Hg] δ 3.19 [s, 3J (Pt–H) = 13.2, 3H, Hh] δ 460 
2.71 [m, 1H, Hg′] δ 2.43 [s, 3J (Pt–H) = 17.2, 3H, Hh′] δ 2.05 [m, 2H, Hf ] δ 1.38 [s, 2J (Pt–H) = 66.0, 461 
3H, Hi] δ 0.79 [s, 2J (Pt–H) = 69.2, 3H, Hj]. In addition, resonances corresponding to a minor isomer 462 
(<10%) were observed at δ 8.45 [s, 3J (Pt–H) = 40.0, 1H, Hd] δ 7.38 [d, 3J(H–H) = 8.0, 1H, Ha] δ 7.07 463 
[dd, 3J(H–H) = 8.0, 4J(H–H) = 2.0, 1H, Hb] δ 2.93 [s, 3J (Pt–H) = 16.0, 3H, Hh] δ 2.45 [s, 3J (Pt–H) = 464 
16.0, 3H, Hh′] δ 1.23 [s, 2J (Pt–H) = 65.3, 3H, Hi] δ 0.61 [s, 2J (Pt–H) = 71.5, 3H, Hj]. Anal. calc. for 465 
C14H22ClN2Pt (%): C, 29.20; H, 3.85; N, 4.87. Found (%): C, 29.00; H, 4.01; N, 4.65. 466 
[Pt(CH3)I2{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (2c) was prepared from 0.060 g (0.11 mmol) of 467 
[PtI{(CH3)2N(CH2)3NCH(4- ClC6H3)}] 1c using the same procedure and a reaction time of 24 hours. 468 
Yield: 0.066 g (73%). 1H-NMR (400 MHz, CDCl3): δ 8.75 [d, 3J (Pt–H) = 39.8, 4J(H–H) = 1.8, 1H, 469 
Ha] δ 8.22 [s, 3J (Pt–H) = 104.0, 1H, Hd] δ 7.36 [d, 4J (Pt–H) = 4.8, 3J(H–H) = 8.4, 1H, Hc] δ 7.08 [dd, 470 
3J(H–H) = 8.1, 4J(H–H) = 1.9, 1H, Hb] δ 4.39 [m, 1H, He] δ 3.72 [d, J(H–H) = 17.0,1H, He′] δ 3.64 [s, 471 
3J (Pt–H) = 13.9, 3H, Hh] δ 3.42 [m, 1H, Hf ] δ 2.72 [s, 3J (Pt–H) = 16.1, 3H, Hh′] δ 2.65 [m, 1H, Hf′] δ 472 
2.18 [m, 1H, Hg′] δ 2.07 [m, 1H, Hg] δ 1.71 [s, 3J (Pt–H) = 65.5, 3H, Hj]. ESI-MS(+): 560.9914 [M − 473 
I]+. Anal. calc. for C13H19ClI2N2Pt (%): C, 22.71; H, 2.79; N, 4.07. Found (%): C, 23.11; H, 2.83; N, 474 
4.28.  475 
[PtClI2{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (3a) was obtained from 0.039 g (0.1 mmol) of the 476 
cyclometallated [PtCl{(CH3)2 N(CH2)3NCH(4-ClC6H3)}] 1a dissolved in acetone (15 mL) and 0.023 477 
g (0.1 mmol) of I2 dissolved in acetone (6 mL). The solution was stirred for 75 minutes, the solvent was 478 
removed and 10 mL of diethyl ether were added. The obtained solid was filtered under vacuum. Yield: 479 
0.055 g (90%). 1H-NMR (400 MHz, CDCl3): δ 7.92 [s, 3J (Pt–H) = 95.2, 1H, Hd] δ 7.91 [s, 3J (Pt–H) = 480 
28.0, 1H, Ha] δ 7.46 [d, 3J(H–H) = 8.1, 1H, Hc] δ 7.00 [dd, 3J(H–H) = 8.1, 4J(H–H) = 1.9, 1H, Hb] δ 481 
4.11 [td, 3J(H–H) = 5.3, 4J(H–H) = 1.3, 2H, He] δ 3.44 [s, 3J (Pt–H) = 14.8, 6H, Hh] δ 3.02 [m, 2H, Hg] 482 
δ 2.26 [m, 2H, Hf ]. In addition, resonances corresponding to a minor isomer (<10%) were observed at δ 483 
8.09 [s, 1H, Hd] δ 7.97 [d, 4J(H–H) = 2.0, 1H, Ha] δ 7.45 [d, 3J(H–H) = 8.1, 1H, Hc] δ 7.13 [dd, 3J(H–484 
H) = 8.0, 4J(H–H) = 2.0, 1H, Hb] δ 3.27 [s, 3J (Pt–H) = 16.0, 6H, Hh]. Anal. calc. for 485 
C12H16Cl2I2N2Pt (%): C, 20.36; H, 2.28; N, 3.96. Found (%): C, 20.27; H, 2.32; N, 4.00. 486 
[Pt(CH3)I2{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (3b) was prepared following the same procedure 487 
from 0.080 g (0.2 mmol) of [PtCH3{(CH3)2N(CH2)3NCH(4-ClC6H3)}] 1b and 0.047 g (0.2 mmol) of 488 
I2. Yield: 0.087 g (69%). 1H-NMR (400 MHz, CDCl3): δ 8.16 [s, 3J (Pt–H) = 46.8, 1H, Hd] δ 7.30 [d, 489 
3J(H–H) = 8.0, 1H, Hc] δ 7.21 [d, 3J (Pt–H) = 36.0, 4J(H–H) = 1.8, 1H, Ha] δ 6.85 [dd, 3J(H–H) = 8.0, 490 
4J(H–H) = 1.9, 1H, Hb] δ 4.04 [td, 3J (Pt–H) = 20.8, 3J(H–H) = 5.5, 4J(H–H) = 1.7, 2H, He] δ 3.11 [s, 491 
3J (Pt–H) = 17.6, 6H, Hh] δ 3.05 [m, 2H, Hg] δ 2.21 [s, 3J (Pt–H) = 69.2, 3H, Hi] δ 2.15 [m, 2H, Hf ]. 492 
Anal. calc. for C13H19ClI2N2Pt (%): C, 22.71; H, 2.79; N, 4.07. Found (%): C, 22.94; H, 2.90; N, 3.99. 493 
[PtI3{(CH3)2N(CH2)3NCH(4-ClC6H3)}] (3c) was prepared following the same procedure from 0.080 494 
g (0.11 mmol) of [PtI{(CH3)2N(CH2)3NCH(4-ClC6H3)}] 1c and 0.028 g (0.11 mmol) of I2 and a 495 
reaction time of 2 hours. Yield: 0.073 g (83%). 1H-NMR (400 MHz, CDCl3): δ 8.49 [d, 3J (Pt–H) = 496 
32.7, 4J(H–H) = 1.9, 1H, Ha] δ 7.99 [t, 3J (Pt–H) = 88.0, 4J(H–H) = 1.6, 1H, Hd] δ 7.42 [d, 3J(H–H) = 497 
8.1, 1H, Hc] δ 6.93 [dd, 3J(H–H) = 8.1, 4J(H–H) = 1.9, 1H, Hb] δ 3.97 [td, 3J(H–H) = 5.3, 4J(H–H) = 498 
1.6, 2H, He] δ 3.57 [s, 3J (Pt–H) = 16.8, 6H, Hh] δ 2.93 [m, 2H, Hg] δ 2.33 [m, 2H, Hf ]. ESI-MS(+): 499 
800.7796 [M + H]+. Anal. calc. for C12H16ClI3N2Pt (%): C, 18.03; H, 2.01; N, 3.51. Found (%): C, 500 
18.41; H, 2.01; N, 3.51. 501 
 502 
Stability and behavior in the presence of ascorbic acid by NMR measurements 503 
The stability of the platinum(IV) compounds under investigation in aqueous solution was monitored by 504 
1H NMR spectroscopy at ambient temperature. Samples were analyzed in the Nuclear Magnetic 505 
Resonance Unit, Scientific and Technological Centers of the University of Barcelona (CCiTUB). The 506 
solutions of the complexes were prepared in 50 mM phosphate buffer (in D2O, pD 7,40) and a minimum 507 
amount (2 drops) of d6-DMSO for the solubilization of the compound. The final concentration of the 508 
complex was 1 mM and 1H NMR spectra were recorded with a Varian 400 and a Bruker 400 509 
spectrometer at time periods between 0 h and 10 days. For monitoring the reactivity of the studied 510 
compounds with ascorbic acid, the samples were prepared under the same conditions as described above 511 
with a final concentration of the complex and ascorbic acid of 1 mM and 25 mM, respectively. 1H NMR 512 
spectra were recorded over the same time period as described above. 513 
The stability of compound 2b in aqueous solution: the resonances assigned to the single species initially 514 
formed and stable up to ten days are given. δ = 8.59 [s, 3J(H–Pt) = 52, imine], {7.38 [d], 7.27 [s], 7.10 515 
[d], aromatics}, {0.92 [s, 3J(H–Pt) = 64 ], 0.65 [s, 3J(H–Pt) = 80], MePt}. The reactivity of compound 516 
2b with ascorbic acid in aqueous solution: the resonances assigned to a single species initially formed 517 
and stable up to ten days are given. δ = 8.59 [s, 3J(H–Pt) = 52, imine], {7.38 [d], 7.27 [s], 7.10 [d], 518 
aromatics}, {0.92 [s, 3J(H–Pt) = 64 ], 0.45 [s, 3J(H–Pt) = 56], MePt}.  519 
The stability of compound 2c in aqueous solution: the resonances assigned to two observed species are 520 
given. Initial compound: δ = 8.26 [s, imine], {8.49 [d, Ha], 7.45 [d], 7.18 [d], aromatics}, 1.52 [s, MePt]. 521 
The second compound is formed and its relative intensity increases with time. δ = 8.34 [s, imine], {7.25 522 
[d], 6.98 [dd], aromatics}, 1.10 [s, MePt]. 523 
The reactivity of compound 2c with ascorbic acid in aqueous solution: the resonances assigned to a 524 
single species initially formed and stable up to 72 hours are given. δ = 7.75 [s, imine], {8.26 [d, Ha], 525 
7.25 [d], 7.08 [d], aromatics}, 1.10 [s, MePt]. 526 
 527 
X-ray diffraction 528 
Suitable crystals of compounds 1c, 3b and 3a′ were grown at room temperature in dichloromethane–529 
methanol. X-ray diffraction data were collected for prism-like specimens on a D8 VENTURE system 530 
equipped with a multilayer monochromator and a Mo high brilliance Incoatec Microfocus Source (λ = 531 
0.71073 Å) at 100 K (1c and 3b) or at 293 K (3a′). The structures were solved and refined using the 532 
Bruker SHELXTL software package.70 Crystallographic details are given in Table 3. 533 
 534 
Biological studies 535 
Cell culture and cell viability assay. Human lung adenocarcinoma A-549 cells and human breast 536 
adenocarcinoma cells were grown as a monolayer culture in minimum essential medium (DMEM with 537 
L-glutamine, without glucose and without sodium pyruvate) with the addition of 10% heat-inactivated 538 
Fetal Calf Serum (FCS), 10 mM D-glucose and 0.1% streptomycin/penicillin, under standard culture 539 
conditions (humidified air with 5% CO2 at 37 °C). Human breast adenocarcinoma MCF-7 cells were 540 
cultured in MEM without phenol red, containing 10% Fetal Bovine Serum (FBS), 10 mM D-glucose, 1 541 
mM sodium pyruvate, 2 mM L-glutamine, 0.1% streptomycin/penicillin, 0.01 mg mL−1 insulin, and 1% 542 
nonessential amino acids. Human colorectal carcinoma HCT116 cells were cultured in a DMEM/HAM 543 
F12 (1 : 1 volume) mixture containing 10% FBS, 4 mM L-glutamine, 12.5 mM D-glucose and 0.1% 544 
streptomycin/penicillin. 545 
For all viability assays, compounds were suspended in high purity DMSO at 20 mM as a stock solution. 546 
To obtain the final assay concentrations, they were diluted in DMEM (Dulbecco’s Modified Eagle’s 547 
Medium) (the final concentration of DMSO was the same for all conditions, and was always lower than 548 
1%). The assay was performed by a variation of the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-549 
diphenyltetrazolium bromide) assay described by Mosmann et al.71 and Matito and coworkers72 which 550 
is based on the ability of live cells to cleave the tetrazolium ring of the MTT thus producing formazan, 551 
which absorbs at 550 nm. In brief, the corresponding number of cells per well (2.5 × 103 A-549 cells per 552 
well, 5 × 103 MDA-MB-231 cells per well, 1 × 104 MCF-7 cells per well and 2 × 103 HCT-116 cells 553 
per well) were cultured in 96 well plates for 24 hours prior to the addition of different compounds at 554 
different concentrations, in triplicate. After incubation of the cells with the compounds for 72 h more, 555 
the media were aspirated and 100 μL of filtered MTT (0.5 mg mL−1) were added to each well. 556 
Following 1 h of incubation with the MTT, the supernatant was removed and the precipitated formazan 557 
was dissolved in 100 μL DMSO. Relative cell viability, compared to the viability of untreated cells, was 558 
measured by absorbance at 550 nm on an ELISA plate reader (Tecan Sunrise MR20-301, TECAN, 559 
Salzburg, Austria). Concentrations that inhibited cell growth by 50% (IC50) after 72 h of treatment were 560 
subsequently calculated. 561 
 562 
DNA migration studies 563 
A stock solution (10 mM) of each compound was prepared in high purity DMSO. Then, serial dilutions 564 
were made in MilliQ water (1 : 1). Plasmid pBluescript SK+ (Stratagene) was obtained using a 565 
QIAGEN plasmid midi kit as described by the manufacturer. The interaction of drugs with pBluescript 566 
SK+ plasmid DNA was analysed by agarose gel electrophoresis following a modification of the method 567 
described by Abdullah et al.73 Plasmid DNA aliquots (40 μg mL−1) were incubated in TE buffer (10 568 
mM Tris-HCl, 1 mM EDTA, pH 7.5) with different concentrations of compounds 1a–1c, 2a–2c and 3a–569 
3c, ranging from 0 μM to 200 μM at 37 °C for 24 h. The final DMSO concentration in the reactions was 570 
always lower than 1%. For comparison, cisplatin and ethidium bromide (EB) were used as reference 571 
controls. The aliquots of 20 μL of the incubated solutions containing 0.8 μg of DNA were subjected to 572 
1% agarose gel electrophoresis in TAE buffer (40 mM tris-acetate, 2 mM EDTA, pH 8.0). The gel was 573 
stained in TAE buffer containing ethidium bromide (0.5 mg mL−1) and visualized and photographed 574 
under UV light. 575 
The same experimental procedure was carried out incubating plasmid DNA with the platinum(IV) 576 
complexes 2a–2c and 3a–3c (25–200 μM) in the absence or presence of ascorbic acid (500 μM) in a 577 
0.1× Tris-EDTA buffer (pH 7.8) for 24 h at 37 °C, as described elsewhere.67 578 
 579 
Topoisomerase inhibition assays 580 
Topoisomerase I-based experiments were performed as described previously.49 Supercoiled pBluescript 581 
DNA, obtained as described above, was treated with topoisomerase I in the absence or presence of 582 
increasing concentrations of compounds 2a–2c and 3a–3c. Assay mixtures contained supercoiled 583 
pBluescript DNA (0.8 μg), calf thymus topoisomerase I (3 units) and complexes 2a–2c and 3a–3c (0–584 
100 μM) in 20 μL of relaxation buffer Tris-HCl buffer (pH 7.5) containing 175 mM KCl, 5 mM MgCl2 585 
and 0.1 mM EDTA. Ethidium bromide (EB, 10 μM) was used as a control of intercalating agents and 586 
etoposide (E, 100 μM) as a control of the non-intercalating agent. Reactions were incubated for 30 min 587 
at 37 °C and stopped by the addition of 2 μL of agarose gel loading buffer. Samples were then subjected 588 
to electrophoresis and DNA bands were stained with ethidium bromide as described above. 589 
The DNA topoisomerase IIα inhibitory activity of the compounds tested in this study was measured as 590 
described elsewhere50 with a few modifications. Supercoiled pBluescript DNA was incubated with 591 
topoisomerase IIα (Affymetrix) in the absence or presence of increasing concentrations of compounds 592 
under analysis. Assay mixtures contained supercoiled pBluescript DNA (0.3 μg), topoisomerase IIα (4 593 
units) and the tested compounds (0–100 μM) in 20 μL of 1× TopoII reaction buffer (PN73592 594 
Affymetrix, Inc.). Etoposide was used at 100 and 50 μM concentration as a control of the topo IIα 595 
inhibitor. Reactions were incubated for 45 min at 37 °C and stopped by the addition of 2 μL of agarose 596 
gel loading buffer. Samples were then subjected to electrophoresis and DNA bands were stained with 597 
ethidium bromide as described above (0.5 μg mL−1) for 30 min and visualized by transillumination. 598 
 599 
Cathepsin B inhibition assay 600 
The colorimetric cathepsin B assay was performed as described by Casini et al.74 with a few 601 
modifications. Briefly, the reaction mixture contained 100 mM sodium phosphate (pH 6.0), 1 mM 602 
EDTA and 200 μM sodium N-carbobenzoxy- L-lysine p-nitrophenyl ester as a substrate. To make the 603 
enzyme catalytically active before each experiment, the cysteine in the active site was reduced by 604 
treatment with dithiothreitol (DTT). For this purpose, 5 mM DTT was added to the cathepsin B sample, 605 
before dilution, and incubated 1 h at 30 °C. To test the inhibitory effect of the platinum compounds on 606 
cathepsin B, activity measurements were performed in triplicate using fixed concentrations of the 607 
enzyme (1 μM) and the substrate (200 μM). The platinum compounds were used at concentrations 608 
ranging from 5 to 100 μM. Prior to the addition of the substrate, cathepsin B was incubated with the 609 
different compounds at 25 °C for 2 h. The cysteine proteinase inhibitor E-64 was used as a positive 610 
control of cathepsin B inhibition. Complete inhibition was achieved at 10 μM concentration of E-64. 611 
Activity was measured over 90 s at 326 nm on a UV spectrophotometer. 612 
 613 
Cell cycle analysis 614 
Cell cycle was assessed by flow cytometry using a fluorescence activated cell sorter (FACS). For this 615 
assay, 4 × 104 A-549 cells were seeded in 6 well plates with 2 mL of growth medium. After 24 h of 616 
incubation, compounds 2b or 2c were added at their IC50 values 2.62 and 1.42 μM, respectively. 617 
Following 72 h of incubation, cells were harvested by mild trypsinization, collected by centrifugation 618 
and resuspended in Tris buffered saline solution (TBS) containing 50 mg mL−1 PI, 10 mg mL−1 619 
DNase-free RNase and 0.1% Igepal CA-630. The cell suspension was incubated for 1 h at room 620 
temperature to allow for the staining of the cells with PI, and afterwards FACS analysis was carried out 621 
at 488 nm by employing a Gallios flow cytometer (Beckman Coulter). Data from 1 × 104 cells were 622 
collected and analyzed using the FlowJo software. 623 
 624 
Apoptosis assay 625 
Apoptosis was assessed by evaluating the annexin-V binding to phosphatidylserine (PS), which is 626 
externalized early in the apoptotic process. 4 × 104 A-549 cells per well were seeded in 6 well plates 627 
with 2 mL of medium and treated as described for the cell cycle analysis assay. After cell collection and 628 
centrifugation, the cells were resuspended in 95 μL binding buffer (10 mM HEPES/NaOH, pH 7.40, 140 629 
mM NaCl, 2.5 mM CaCl2). 3 μL of the Annexin-V FITC conjugate (1 mg mL−1) were then added and 630 
the suspension was incubated in the dark for 30 min, at room temperature. The cell suspension was 631 
added to a vial containing 500 μL of binding buffer, stained with 20 μL of 1 mg mL−1 PI solution and 632 
analyzed. Data from 1 × 104 cells were collected and analyzed using the FlowJo software. 633 
 634 
Determination of intracellular reactive oxygen species (ROS) levels 635 
4 × 104 A-549 cells per well were seeded in 6 well plates with 2 mL of growth medium and treated as 636 
described for the cell cycle analysis assay. First, the cells were washed once with warm PBS, and 637 
incubated with 5 μM 2′,7′-dichlorofluorescein diacetate (DCFH-DA, Invitrogen) in PBS supplemented 638 
with 10 mM glucose and 2 mM glutamine for 30 min at 37 °C. Then, DCFH-DA solution in PBS was 639 
replaced with the complete culture medium and the cells were incubated for another 30 min at 37 °C. 640 
Finally, the cells were trypsinized and resuspended thoroughly in 0.4 mL of PBS containing DCFH-DA 641 
(50 μM) and PI (20 μg mL−1).75 The intracellular internalized probe reacts with ROS and emits 642 
fluorescence when excited at 492 nm. Emitted fluorescence was recorded by flow cytometry at 520 nm 643 
using a Gallios flow cytometer (Beckman Coulter). The data of DCF fluorescence concentrations from 1 644 
× 104 PI negative cells were collected and analysed using FlowJo software. 645 
Data analysis. For each compound, a minimum of three independent experiments with triplicate values 646 
were conducted to measure cell viability. A minimum of two independent experiments in triplicates 647 
were performed for cell cycle analysis, assessment of apoptosis and ROS. Significant differences 648 
compared to the control were assessed by Student’s t-test where p < 0.05(*), p < 0.01(**) or p < 649 
0.001(***) were taken into consideration. Data are given as the mean ± standard deviation (SD). 650 
  651 
ACKNOWLEDGEMENTS 652 
 653 
This work was supported by the Ministerio de Economia y Competitividad (Grants CTQ-2015-65040-P, 654 
CTQ-2015-65707- C2-1-P MINECO/FEDER, “Red de Excelencia MetalBio” CTQ 2015-71211-REDT, 655 
SAF2014-56059-R, and SAF2015-70270- REDT) and by the Generalitat de Catalunya (Grants 656 
2014SGR-1017 and 2014SGR-00155, and Icrea Academia award 2015 granted to M. Cascante). The 657 
efficient contribution of Dr Francisco Cárdenas and Dra. A. Linares for NMR spectroscopy at the 658 
Scientific and Technological Centers of the University of Barcelona (CCiTUB) is gratefully 659 
acknowledged. 660 
  661 
REFERENCES 662 
 663 
1  T. C. Johnstone, K. Suntharalingam and S. J. Lippard, Chem. Rev., 2016, 116, 3436–3486. 664 
2  U. Basu, B. Banik, R. Wen, R. K. Pathak and S. Dhar, Dalton Trans., 2016, 12992–13004. 665 
3  D. Gibson, Dalton Trans., 2016, 12983–12991. 666 
4  G. R. Kenny, S. W. Chuah, A. Crawford and C. J. Marmion, Eur. J. Inorg. Chem., 2017, 1596–667 
1612. 668 
5  D. A. K. Vezzu, Q. Lu, Y. H. Chen and S. Huo, J. Inorg. Biochem., 2014, 134, 49–56. 669 
6  R. W.-Y. Sun, D.-L. Ma, E. L.-M. Wong and C.-M. Che, Dalton Trans., 2007, 4884–4892. 670 
7  G. L. Edwards, D. S. Black, G. B. Deacon and L. P. Wakelin, Can. J. Chem., 2005, 83, 969–979. 671 
8  G. L. Edwards, D. S. Black, G. B. Deacon and L. P. Wakelin, Can. J. Chem., 2005, 83, 980–989. 672 
9  D. L. Ma and C. M. Che, Chem. – Eur. J., 2003, 9, 6133–6144. 673 
10  P. K. M. Siu, D. L. Ma and C. M. Che, Chem. Commun., 2005, 1, 1025–1027. 674 
11  R. W.-Y. Sun, A. L.-F. Chow, X.-H. Li, J. J. Yan, S. S.-Y. Chui and C.-M. Che, Chem. Sci., 675 
2011, 2, 728. 676 
12  H. L. Chan, D. L. Ma, M. Yang and C. M. Che, ChemBioChem, 2003, 4, 62–68. 677 
13  J. Albert, R. Bosque, M. Crespo, J. Granell, C. López, R. Cortés, A. Gonzalez, J. Quirante, C. 678 
Calvis, R. Messeguer, L. Baldomà, J. Badia and M. Cascante, Bioorg. Med. Chem., 2013, 21, 679 
4210–4217. 680 
14  J. Albert, R. Bosque, M. Crespo, J. Granell, C. López, R. Martín, A. González, A. Jayaraman, J. 681 
Quirante, C. Calvis, J. Badía, L. Baldomà, M. Font-Bardia, M. Cascante and R. Messeguer, 682 
Dalton Trans., 2015, 44, 13602–13614. 683 
15  R. Cortés, M. Crespo, L. Davin, R. Martín, J. Quirante, D. Ruiz, R. Messeguer, C. Calvis, L. 684 
Baldomà, J. Badia, M. Font-Bardía, T. Calvet and M. Cascante, Eur. J. Med. Chem., 2012, 54, 685 
557–566. 686 
16  A. Escolà, M. Crespo, J. Quirante, R. Cortés, A. Jayaraman, J. Badia, L. Baldoma, T. Calvet, M. 687 
Font-Bardia and M. Cascante, Organometallics, 2014, 33, 1740–1750. 688 
17  A. Escolà, M. Crespo, C. López, J. Quirante, A. Jayaraman, I. H. Polat, J. Badía, L. Baldomà 689 
and M. Cascante, Bioorg. Med. Chem., 2016, 24, 5804–5815. 690 
18  C. M. Anderson, M. W. Greenberg, L. Spano, L. Servatius and J. M. Tanski, J. Organomet. 691 
Chem., 2016, 819, 27–36. 692 
19  C. M. Anderson, M. Crespo, M. C. Jennings, A. J. Lough, G. Ferguson and R. J. Puddephatt, 693 
Organometallics, 1991, 10, 2672–2679. 694 
20  T. Calvet, M. Crespo, M. Font-Bardía, S. Jansat and M. Martínez, Organometallics, 2012, 31, 695 
4367–4373. 696 
21  M. Crespo, C. Grande and A. Klein, J. Chem. Soc., Dalton Trans., 1999, 1629–1638. 697 
22  M. Crespo, C. Grande, A. Klein, M. Font-Bardía and X. Solans, J. Organomet. Chem., 1998, 698 
563, 179–190. 699 
23  J. A. Labinger, Organometallics, 2015, 34, 4784–4795. 700 
24  L. Rendina and R. J. Puddephatt, Chem. Rev., 1997, 97, 1735–1754. 701 
25  T. C. Johnstone, S. M. Alexander, J. J. Wilson and S. J. Lippard, Dalton Trans., 2015, 44, 119–702 
129. 703 
26  J. J. Wilson and S. J. Lippard, Chem. Rev., 2014, 114, 4470–4495. 704 
27  Z. Xu, Z. Wang, S.-M. Yiu and G. Zhu, Dalton Trans., 2015, 44, 19918–19926. 705 
28  J. Z. Zhang, P. Bonnitcha, E. Wexselblatt, A. V. Klein, Y. Najajreh, D. Gibson and T. W. 706 
Hambley, Chem. – Eur. J., 2013, 19, 1672–1676. 707 
29 M. Ravera, E. Gabano, G. Pelosi, F. Fregonese, S. Tinello and D. Osella, Inorg. Chem., 2014, 708 
53, 9326–9335. 709 
30  M. Ravera, E. Gabano, M. Sardi, E. Monti, M. B. Gariboldi and D. Osella, Eur. J. Inorg. Chem., 710 
2012, 21, 3441–3448. 711 
31  T. C. Johnstone, J. J. Wilson and S. J. Lippard, Inorg. Chem., 2013, 52, 12234–12249. 712 
32  M. Ghedini, D. Pucci, A. Crispini and G. Barberio, Organometallics, 1999, 18, 2116–2124. 713 
33  C. M. Anderson, M. Crespo, M. Font-Bardia and X. Solans, J. Organomet. Chem., 2000, 604, 714 
178–185. 715 
34  C. M. Anderson, M. Crespo and F. D. Rochon, J. Organomet. Chem., 2001, 631, 164–174. 716 
35  J. Rodríguez, J. Zafrilla, J. Albert, M. Crespo, J. Granell, T. Calvet and M. Font-Bardia, J. 717 
Organomet. Chem., 2009, 694, 2467–2475. 718 
36  A. Capapé, M. Crespo, J. Granell, M. Font-Bardía and X. Solans, J. Organomet. Chem., 2005, 719 
690, 4309–4318. 720 
37  A. Gandioso, J. Valle-Sistac, L. Rodríguez, M. Crespo and M. Font-Bardía, Organometallics, 721 
2014, 33, 561–570. 722 
38  D. Musumeci, C. Platella, C. Riccardi, A. Merlino, T. Marzo, L. Massai, L. Messori and D. 723 
Montesarchio, Dalton Trans., 2016, 2, 8587–8600. 724 
39  D. Cirri, S. Pillozzi, C. Gabbiani, J. Tricomi, G. Bartoli, M. Stefanini, E. Michelucci, A. 725 
Arcangeli, L. Messori and T. Marzo, Dalton Trans., 2017, 46, 3311–3317. 726 
40  A. M. Basri, R. M. Lord, S. J. Allison, A. Rodríguez-Bárzano, S. J. Lucas, F. D. Janeway, H. J. 727 
Shepherd, C. M. Pask, R. M. Phillips and P. C. McGowan, Chem. – Eur. J., 2017, 23, 6341–728 
6356. 729 
41  T. A. K. Al-Allaf, L. J. Rashan, A. S. Abu-Surrah, R. Fawzi and M. Steimann, Transition Met. 730 
Chem., 1998, 23, 403–406. 731 
42  S. M. Nabavizadeh, H. Amini, M. Rashidi, K. R. Pellarin, M. S. McCready, B. F. T. Cooper and 732 
R. J. Puddephatt, J. Organomet. Chem., 2012, 713, 60–67. 733 
43  M. Crespo, M. Font-Bardia and M. Martínez, Dalton Trans., 2015, 19543–19552. 734 
44  J. C. Wang, Nat. Rev. Mol. Cell Biol., 2002, 3, 430–440. 735 
45  T. Li and L. F. Liu, Annu. Rev. Pharmacol. Toxicol., 2001, 53–77. 736 
46  M. M. Heck and W. C. Earnshaw, J. Cell Biol., 1986, 103, 2569–2581. 737 
47  C. Wang, J. Qin and S. Yuermao, Drug Discoveries Ther., 2012, 6, 230–237. 738 
48  J. L. Nitiss, Biochim. Biophys. Acta, Gene Struct. Expression, 1998, 1400, 63–81. 739 
49  D. S. Sappal, A. K. McClendon, J. A. Fleming, V. Thoroddsen, K. Connolly, C. Reimer, R. K. 740 
Blackman, C. E. Bulawa, N. Osheroff, P. Charlton and L. A. Rudolph-Owen, Mol. Cancer 741 
Ther., 2004, 3, 47–58. 742 
50  P. Thapa, K. Y. Jun, T. M. Kadayat, C. Park, Z. Zheng, T. B. Thapa Magar, G. Bist, A. Shrestha, 743 
Y. Na, Y. Kwon and E. S. Lee, Bioorg. Med. Chem., 2015, 23, 6454–6466. 744 
51  J. Spencer, A. Casini, O. Zava, R. P. Rathnam, S. K. Velhanda, M. Pfeffer, S. K. Callear, M. B. 745 
Hursthoused and P. J. Dyson, Dalton Trans., 2009, 10731–10735.  746 
52  S. Diaz-Moralli, M. Tarrado-Castellarnau, A. Miranda and M. Cascante, Pharmacol. Ther., 747 
2013, 138, 255–271. 748 
53  M. Zanuy, A. Ramos-Montoya, O. Villacañas, N. Canela, A. Miranda, E. Aguilar, N. Agell, O. 749 
Bachs, J. Rubio- Martinez, M. D. Pujol, W.-N. P. Lee, S. Marin and M. Cascante, 750 
Metabolomics, 2012, 8, 454–464. 751 
54  M. Malumbres and M. Barbacid, Cancer Cell, 2006, 9, 2–4. 752 
55  G. R. Bean, Y. T. Ganesan, Y. Dong, S. Takeda, H. Liu, P. M. Chan, Y. Huang, L. A. Chodosh, 753 
G. P. Zambetti, J. J.-D. Hsieh and E. H.-Y. Cheng, Sci. Signaling, 2013, 6(268), ra20. 754 
56  D. Hanahan and R. A. Weinberg, Cell, 2011, 144, 646–674. 755 
57  B. Pucci, M. Kasten and A. Giordano, Neoplasia, 2000, 2, 291–299. 756 
58  D. L. Bratton, E. Dreyer, J. M. Kailey, V. A. Fadok, K. L. Clay and P. M. Henson, J. Immunol., 757 
1992, 148, 514–523. 758 
59  A. K. Hammill, J. W. Uhr and R. H. Scheuermann, Exp. Cell Res., 1999, 251, 16–21. 759 
60  M. W. Lee, S. Ch. Parkb, Y. G. Yang, S. O. Yim, H. S. Chae, J.-H. Bach, H. J. Lee, K. Y. Kim, 760 
W. B. Lee and S. S. Kim, FEBS Lett., 2002, 512, 313–318. 761 
61  E. Giannoni, F. Buricchi, G. Raugei, G. Ramponi and P. Chiarugi, Mol. Cell Biol., 2005, 25, 762 
6391–6403. 763 
62  P. Gao, H. Zhang, R. Dinavahi, F. Li, Y. Xiang, V. Raman, Z. M. Bhujwalla, D. W. Felsher, L. 764 
Cheng, J. Pevsner, L. A. Lee, G. L. Semenza and C. V. Dang, Cancer Cell, 2007, 12, 230–238.  765 
63  A. Takahashi, N. Ohtani, K. Yamakoshi, S.-I. Iida, H. Tahara, K. Nakayama, K. I. Nakayama, T. 766 
Ide, H. Saya and E. Hara, Nat. Cell Biol., 2006, 8, 1291–1297. 767 
64  C. Garrido, L. Galluzzi, M. Brunet, P. E. Puig, C. Didelot and G. Kroemer, Cell Death Differ., 768 
2006, 13, 1423–1433. 769 
65  A. Miyajima, J. Nakashima, K. Yoshioka, M. Tachibana, H. Tazaki and M. Murai, Br. J. 770 
Cancer, 1997, 76, 206–210. 771 
66  S. Dasari and P. B. Tchounwou, Eur. J. Pharmacol., 2014, 740, 364–378. 772 
67  S. Göschl, P. V. Hristo, S. Theiner, M. A. Jakupec, M. Galanski and B. K. Keppler, J. Inorg. 773 
Biochem., 2016, 160, 264–274. 774 
68  V. Pichler, S. Göschl, E. Schreiber-Brynzak, M. A. Jakupec, M. Galanski and B. K. Keppler, 775 
Metallomics, 2015, 7, 1078–1090. 776 
69  G. S. Hill, M. J. Irwin, C. J. Levy, L. M. Rendina and R. J. Puddephatt, Inorg. Synth., 1998, 32, 777 
149–153. 778 
70  G. M. Sheldrick, Acta Crystallogr., Sect. C: Cryst. Struct. Commun., 2015, 71, 3–8. 779 
71  T. Mosmann, J. Immunol. Methods, 1983, 65, 55–63. 780 
72  C. Matito, F. Mastorakou, J. J. Centelles, J. L. Torres Simón and M. C. Serratosa, Eur. J. Nutr., 781 
2003, 42, 43–49. 782 
73  A. Abdullah, F. Huq, A. Chowdhury, H. Tayyem, P. Beale and K. Fisher, BMC Chem. Biol., 783 
2006, 6, 3. 784 
74  A. Casini, C. Gabbiani, F. Sorrentino, M. P. Rigobello, A. Bindoli, T. J. Geldbach, A. Marrone, 785 
N. Re, C. G. Hartinger, P. J. Dyson and L. Messori, J. Med. Chem., 2008, 51, 6773–6781. 786 
75  M. Tarrado-Castellarnau, R. Cortés, M. Zanuy, J. Tarragó-Celada, I. H. Polat, R. Hill, T. W. M. 787 
Fan, W. Link and M. Cascante, Pharmacol. Res., 2015, 102, 218–234. 788 
789 
Legends to figures 790 
 791 
Scheme 1 Possible pathways in the synthesis of cyclometallated platinum(IV) compounds. Method A: 792 
intramolecular C–Z oxidative addition observed for Z = Br or Cl. Method B: intermolecular YZ 793 
oxidative addition on a cyclometallated platinum(II) compound obtained for Z = H. L = labile ligand. 794 
 795 
Scheme 2 Synthesis of cyclometallated platinum(II) compounds. (i) +cis-[PtCl2(dmso)2]/NaCH3COO 796 
(1 : 1 : 1) in refluxing methanol, 72 hours; (ii) +[Pt2(CH3)4{μ-S(CH3)2}2] (1 : 0.5) in refluxing 797 
toluene, 1 hour; (iii) +cis-[PtI2(dmso)2]/NaCH3COO (1 : 1 : 1) in refluxing methanol, 48 hours. 798 
 799 
Figure. 1 Molecular structure of compound 1c showing 50% probability ellipsoids. Selected bond 800 
lengths (Å) and angles (°) with estimated standard deviations: Pt(1)–C(1): 2.002(3); Pt(1)–N(1): 801 
2.031(2); Pt(1)–N(2): 2.199(2); Pt(1)–I(1): 2.5925(2); C(1)–Pt(1)–N(1): 80.64(10); N(1)–Pt(1)–N(2): 802 
94.96(9); C(1)–Pt(1)–I(1): 92.91(7); N(2)–Pt(1)–I(1): 91.36(6). 803 
 804 
Scheme 3 Oxidative addition reactions (including the numbering scheme used in the Experimental 805 
section and in Table 1). 806 
 807 
Scheme 4 Possible isomers of compounds 2b and 3a leading to a mutually cis arrangement of Y and Z 808 
ligands. 809 
 810 
Figure. 2  Molecular structure of compound 3b (molecule A) showing 50% probability ellipsoids. 811 
Selected bond lengths (Å) and angles (°) with estimated standard deviations: Pt(1A)–C(1A): 2.016(2); 812 
Pt(1A)–C(13A): 2.074(2); Pt(1)–N(1A): 2.1364(19); Pt(1A)–N(2A): 2.2672(19); Pt(1A)–I(1A): 813 
2.6463(2); Pt(1A)–I(2A): 2.64964(18); C(1A)–Pt(1A)–C(13A): 94.80(9); C(1A)–Pt(1A)–N(1A): 814 
79.76(81); C(13A)–Pt(1A)–N(2A): 91.01(8); N(1A)–Pt(1A)–N(2A): 94.44(7); C(1A)–Pt(1A)–I(1A): 815 
84.01(6); C(13A)–Pt(1A)–I(1A): 88.52(7); N(1A)–Pt(1A)–I(1A): 90.10(5); N(2A)–Pt(1A)–I(1A): 816 
96.70(5); C(13A)–Pt(1A)–I(2A): 91.57(7); C(1A)–Pt(1A)–I(2A): 86.14(6); N(1A)–Pt(1A)–I(2A): 817 
88.88(5); N(2A)–Pt(1A)–I(2A): 93.17(5). 818 
 819 
Figure. 3 Molecular structure of compound 3a’ showing 50% probability ellipsoids. Selected bond 820 
lengths (Å) and angles (°) with estimated standard deviations: Pt(1)–C(1): 2.021(6); Pt(1)–Cl(1): 821 
2.465(5); Pt(1)–N(1): 2.054(6); Pt(1)–N(2): 2.280(6); Pt(1)–I(1): 2.7568(5); Pt(1)–I(2): 2.6331(5); C(1)–822 
Pt(1)–N(1): 80.5(3); N(1)–Pt(1)–N(2): 95.3(2); C(1)–Pt(1)–Cl(1): 83.3(2); C(1)–Pt(1)–Cl(1): 89.18(19); 823 
N(2)–Pt(1)–Cl(1): 94.83(18); C(1)–Pt(1)–I(2): 94.3(2); N(2)–Pt(1)–I(2): 89.83(15); Cl(1)–Pt(1)–I(2): 824 
87.59(9); C(1)–Pt(1)–I(1): 88.88(19); N(1)–Pt(1)–I(1): 87.21(17); N(2)–Pt(1)–I(1): 92.75(16); I(2)–825 
Pt(1)–I(1): 95.368(16). 826 
Scheme 5 Proposed species formed in solution (the charges of the ionic species are omitted). 827 
 828 
Figure. 4 Antiproliferative activity of platinum(II) compounds 1a–1c, platinum(IV) compounds 2a–2c 829 
and 3a–3c, and cisplatin (IC50 μM) against A-549 lung, HCT-116 colon, MDA-MB-231 and MCF-7 830 
breast human cancer cell lines. 831 
 832 
Figure 5. Interaction of pBluescript SK+ plasmid DNA (0.8 μg) with increasing concentrations of 833 
compounds 1a–1c, 2a–2c, 3a–3c, cisplatin and ethidium bromide (EB). Lane 1: DNA only. Lane 2: 2.5 834 
μM. Lane 3: 5 μM. Lane 4: 10 μM. Lane 5: 25 μM. Lane 6: 50 μM. Lane 7: 100 μM. Lane 8: 200 μM. sc 835 
= supercoiled closed circular DNA; oc = open circular DNA. 836 
 837 
Figure 6 Electrophoretograms of supercoiled pBluescript SK+ plasmid DNA incubated with increasing 838 
concentrations of platinum(IV) compounds 2a–2c and 3a–3c in the absence (−AA) or presence (+AA) of 839 
ascorbic acid (500 μM) for 24 h at 37 °C in 0.1× Tris-EDTA buffer (pH 7.8). Lane 1: (−) scDNA only. 840 
Lane 2: 25 μM. Lane 3: 50 μM. Lane 4: 100 μM. Lane 5: 200 μM. 841 
 842 
Figure 7 Analysis of compounds 2a–2b and 3a–3c as putative topoisomerase IIα inhibitors. Supercoiled 843 
pBluescript SK+ plasmid DNA was incubated with topoisomerase IIα (4 units) with increasing 844 
concentrations of the compounds under study. Reactions containing etoposide (Et) are included as 845 
examples of a topoisomerase IIα inhibitor. Lane 1: (−) scDNA only. Lane 2: 0 μM; Lane 3: 5 μM; Lane 846 
4: 10 μM; Lane 5: 25 μM; Lane 6: 50 μM; Lane 7: 100 μM; Lane 8: 150 μM; Lane 9: 200 μM 847 
compound. Except for line 1, all lines included topoisomerase IIα. The conversion of supercoiled DNA 848 
to relaxed DNA was analyzed after 45 min incubation at 37 °C. sc = supercoiled closed circular DNA; R 849 
= relaxed DNA. 850 
 851 
Figure 8 Cell cycle phase distribution at 72 h incubation with compounds 2b and 2c at their IC50 852 
concentration in the A-549 lung adenocarcinoma cell line. Cells were stained with propidium iodide (PI) 853 
and their DNA content was analyzed by flow cytometry. 854 
 855 
Figure 9 Percentage variations of alive, early apoptotic and late apoptotic/necrotic cell populations at 72 856 
h incubation with compounds 2b and 2c at their IC50 concentration in the A-549 lung adenocarcinoma 857 
cell line. Cells were stained with propidium iodide (PI) and FITC-annexin and were analyzed by flow 858 
cytometry. 859 
 860 
Figure 10 ROS levels after 72 h incubation with compounds 2b and 2c at their IC50 concentration in the 861 
A-549 lung adenocarcinoma cell line. 862 
  863 
SCHEME 1 864 
 865 
 866 
 867 
  868 
SCHEME 2 869 
 870 
 871 
 872 
 873 
 874 
  875 
FIGURE 1 876 
 877 
 878 
 879 
 880 
  881 
SCHEME 3 882 
 883 
 884 
 885 
 886 
 887 
  888 
 889 
SCHEME 4 890 
 891 
 892 
 893 
 894 
  895 
 896 
FIGURE 2 897 
 898 
 899 
 900 
  901 
 902 
 903 
FIGURE 3 904 
 905 
 906 
 907 
  908 
SCHEME 5 909 
 910 
 911 
 912 
 913 
 914 
  915 
FIGURE 4 916 
 917 
 918 
 919 
  920 
FIGURE 5 921 
 922 
 923 
 924 
  925 
FIGURE 6 926 
 927 
 928 
  929 
FIGURE 7 930 
 931 
 932 
 933 
 934 
  935 
FIGURE 8 936 
 937 
 938 
  939 
FIGURE 9 940 
 941 
 942 
 943 
 944 
  945 
FIGURE 10 946 
 947 
 948 
  949 
Table 1 Selected 1H NMR data of the studied compoundsa 950 
 951 
 952 
 953 
  954 
Table 2 Antiproliferative activity on A-549 lung, MDA-MB-231 and MCF-7 breast, and HCT-116 for 955 
the studied compounds and cisplatin 956 
 957 
 958 
  959 
Table 3 Crystal data and structure refinement for 1c, 3b and 3a’ 960 
 961 
 962 
 963 
